Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
September 19, 2024 09:45 ET
|
Bavarian Nordic A/S
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
September 19, 2024 09:45 ET
|
Bavarian Nordic A/S
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger...
Gavi indgår aftale med Bavarian Nordic for at sikre hurtig levering af 500.000 doser mpox-vaccine til Afrika
September 18, 2024 04:45 ET
|
Bavarian Nordic A/S
Forhåndskøbsaftalen vil blive finansieret af Gavi’s First Response Fund, som blev etableret efter COVID-19-pandemien med henblik på at sikre hurtig adgang til knappe vaccineforsyninger i fremtidige...
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
September 18, 2024 04:45 ET
|
Bavarian Nordic A/S
The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health...
Bavarian Nordics mpox vaccine opnår prækvalifikation hos WHO
September 13, 2024 05:57 ET
|
Bavarian Nordic A/S
Første mpox-vaccine, der opnår prækvalifikation hos WHOGodkendelsen vil hjælpe med at fremskynde adgangen til vaccinen i alle afrikanske lande KØBENHAVN, Danmark, 13. september 2024 – Bavarian...
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
September 13, 2024 05:57 ET
|
Bavarian Nordic A/S
First mpox vaccine to obtain prequalification by the WHOApproval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024 – Bavarian...
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation
September 12, 2024 04:54 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 12, 2024 – Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS®,...
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation
September 12, 2024 04:54 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 12, 2024 – Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS®,...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
September 06, 2024 12:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 6. september 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
September 06, 2024 12:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding...